Wolfgang Miesbach: Protecting Liver Health in Bleeding Disorders
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a proud post on LinkedIn:
”World Hepatitis Day 2025 – Protecting Liver Health in Bleeding Disorders. Despite curative therapies for hepatitis B and C, people with congenital bleeding disorders (PWBD) remain at elevated risk for liver complications—including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Landmark data show that even after viral eradication, factors such as metabolic dysfunction, obesity, diabetes, and alcohol drive ongoing liver injury.
New International Guidance (EAHAD, EHC, ISTH, WFH) by La Mura et al. provides a unified, evidence-based framework to proactively monitor, prevent, and manage liver complications in PWBD:
– Universal viral hepatitis screening for all PWBD exposed to blood derivatives, including assessment for occult HBV prior to immunosuppression/gene therapy
– Routine metabolic assessment (focus on MASLD and alcohol), as non-viral liver disease now rivals viral hepatitis in this population
– Non-invasive fibrosis stratification using FIB-4 and FibroScan, reducing need for biopsies and identifying patients at risk of progression
– HCC surveillance (liver ultrasound + AFP every 6 months) for those with advanced fibrosis or cirrhosis—even post-cure
– Gene therapy safety: Comprehensive liver evaluation is essential pre- and post-AAV gene therapy; advanced liver disease remains a contraindication”
Read the full article here.
Article: ”The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia”
Journal: JTH (Journal of Thrombosis and Haemostasis)
Authors: Vincenzo La Mura, Massimo Colombo, Graham R. Foster, Paolo Angeli, Wolfgang Miesbach, Robert Klamroth, Glenn F. Pierce, Brian O’Mahony, Ming Y. Lim, Virginia Hernandez-Gea, Michael Makris, Flora Peyvandi
Stay updated on the latest scientific advancements in the field of bleeding disorders with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin